INT201128

Context Info Confidence 0.13 First Reported 2007 Last Reported 2007 Negated 0 Speculated 1 Reported most in Body Documents 1 Total Number 2 Disease Relevance 0.20 Pain Relevance 0.03

plasma membrane (QRFPR) signal transducer activity (QRFPR)

QRFPR (Homo sapiens)

Pain Link Frequency Relevance Heat pruritus 4 53.16 abdominal pain 2 22.48 headache 14 5.00 Bioavailability 4 5.00

Disease Link Frequency Relevance Heat Toxicity 14 79.96 Pruritus 4 53.16 Fatigue 4 49.96 Exanthema 4 46.08 Anorexia 2 23.20 Abdominal Pain 2 22.48 Vomiting 10 21.84 Diarrhoea 6 21.44 Dizziness 20 10.20 Malaria 36 5.00

Sentences Mentioned In

Key:

Protein

Mutation

Event

Anatomy

Negation

Speculation

Pain term

Disease term

The two volunteers who received AQ-13 had received the 100 and 300 mg doses; the two volunteers who received CQ had both received the 1,500 mg dose.

Regulation (received) of AQ-13

1) Confidence 0.13 Published 2007 Journal PLoS Clinical Trials Section Body Doc Link PMC1764434 Disease Relevance 0.20 Pain Relevance 0.03

When the effects of AQ-13 and CQ were analyzed by gender, QTc prolongation was significant only for females after the 600 and 700 mg doses.

Spec (analyzed) Regulation (effects) of AQ-13

2) Confidence 0.08 Published 2007 Journal PLoS Clinical Trials Section Body Doc Link PMC1764434 Disease Relevance 0 Pain Relevance 0

General Comments

This test has worked.